This post was sponsored by Amgen.
Cancer touches everyone. If you’ve been around here, you know that I ride for Cycle for Survival to beat rare cancers every year. We’ve recently experienced the loss of a dear friend who leaves behind two young daughters. When I was invited to check out Amgen’s innovative art activation for their BiTE® technology at the ASCO conference, I jumped at the chance.
What is BiTE® technology?
BiTE (Bispecific T cell Engager) technology is a targeted immuno-oncology platform. It’s engineered to use the immune system to fight cancer. BiTE molecules are designed to engage (or “bridge”) patients’ own immune system cells to a specific protein that appears on the surface of cancer cells. By creating this bridge, the immune system cells are able to more clearly detect and fight cancer cells. Amgen will be sharing more about this new technology with Oncologists at this year’s ASCO conference.
How can you learn more and support Chicago STEM education?
During this year’s ASCO Annual Meeting (May 31 – June 4, 2019), Amgen Oncology will be highlighting how unique science can make a difference in cancer care through a collaboration with two Chicago artists, Nate Baranowski and Shaun Hays. The purpose of the art activation is also to explain the concepts of this complex treatment in terms that we all can understand.
Chalk art installations will be hand-drawn in the following locations in Chicago:
- Saturday, June 1, 2019, 12 – 5 PM at the Field Museum Park Underpass at Roosevelt Road
- Sunday, June 2, 2019, 1 – 5 PM in the plaza in front of the Shedd Aquarium
For every photo or social media post shared of the artwork using #BiTEtheEngager, Amgen Oncology will contribute to a science-based classroom campaign for Chicago Public Schools on DonorsChoose.org.
Please note: This post was sponsored by Amgen. I was compensated to check out this activation. All opinions are my own.